Commission Regulation (EU) 2026/859 of 20 April 2026 amends Annex XIV to REACH Regulation (EC) No 1907/2006. The regulation involves considerations under Article 69(2) of REACH, which requires the European Chemicals Agency to consider whether the use of substances listed in Annex XIV should be subject to restrictions. Companies subject to REACH authorisation requirements should review this amendment for any changes to authorisation obligations.
ECHA opened a public consultation on its draft recommendation to add four substances (currently on the REACH Candidate List as SVHCs) to the REACH Authorisation List (Annex XIV). Stakeholders are invited to submit comments (e.g., information on uses, volumes, supply chain impacts, and potential exemptions) by 2 May 2026. This is a key SVHC-to-authorisation pipeline step: if the European Commission later adds these substances to Annex XIV, continued use/placing on the market after applicable sunset dates would require authorisation for non-exempt uses, affecting manufacturers, importers, and downstream users.
ECHA opened a public consultation on its draft recommendation to add four substances (from the REACH SVHC Candidate List) to the REACH Authorisation List (Annex XIV). Stakeholders are invited to submit comments/information by 2 May 2026. Although this is an Annex XIV pipeline step (not a Candidate List change), it is directly SVHC-relevant because Candidate List substances are the feedstock for Annex XIV recommendations; impacted companies should review uses/supply chains and consider submitting information during the consultation window.
ECHA opened a public consultation on its 13th draft recommendation for prioritising Candidate List SVHCs for inclusion in REACH Annex XIV (Authorisation List). The consultation runs from 2 February 2026 to 2 May 2026. If finalised and later adopted by the European Commission, Annex XIV inclusion would introduce authorisation obligations (including latest application and sunset dates). Compliance teams should review the draft recommendation and background documents, assess portfolio impacts for listed SVHCs, and consider submitting comments.
ECHA has published its 13th draft recommendation proposing four substances for inclusion in REACH Annex XIV (Authorisation List): Bumetrizole (UV-326, EC 223-445-4), 2-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol (UV-329, EC 221-573-5), Triphenyl phosphate (TPP, EC 204-112-2), and 2-(dimethylamino)-2-[(4-methylphenyl)methyl]-1-[4-(morpholin-4-yl)phenyl]butan-1-one (Photoinitiator 379, EC 438-340-0). These substances are proposed for vPvB, endocrine disruptor, and reproductive toxicity properties. Public consultation closes 2 May 2026. Companies in plastics, coatings, adhesives, packaging, and printing industries should assess supply chain exposure and consider submitting comments.
ECHA launched a public consultation on its draft recommendation to the European Commission to add four Candidate List substances to the REACH Authorisation List (Annex XIV). Compliance teams should monitor this pipeline step because Annex XIV inclusion can introduce authorisation obligations for continued use/placing on the market (subject to future sunset dates set in any eventual Annex XIV entries). The consultation is open for stakeholder input until 2 May 2026.
ECHA published supporting documents for its Draft 13th Recommendation of priority substances for potential inclusion in REACH Annex XIV (Authorisation List), including draft Annex XIV entry structures and background/prioritisation documents. This is a draft/pipeline step (not yet a binding Annex XIV amendment), but it signals which SVHCs may be advanced toward authorisation requirements, informing early substitution planning and monitoring of latest application date/sunset date proposals once finalized by the European Commission.
ECHA opened a public consultation on its draft 13th recommendation for prioritising certain Candidate List SVHCs for inclusion in REACH Annex XIV (Authorisation List). The consultation period runs from 2 February 2026 to 2 May 2026. This is a key SVHC-to-authorisation pipeline milestone: affected manufacturers/importers/downstream users should review whether any of the recommended substances are in their supply chains and consider submitting comments, as future Annex XIV inclusion can lead to authorisation obligations and phase-out pressures.
ECHA published the Draft 13th Recommendation and opened a public consultation (2 Feb 2026 to 2 May 2026) on prioritising four SVHCs for potential inclusion in the REACH Authorisation List (Annex XIV): bumetrizole (UV-326), UV-329, triphenyl phosphate, and 2-(dimethylamino)-2-[(4-methylphenyl)methyl]-1-[4-(morpholin-4-yl)phenyl]butan-1-one. This consultation is a key step in the SVHC-to-authorisation pathway; affected companies should assess uses and consider submitting evidence on uses, alternatives, and socio-economic impacts.
ECHA opened a public consultation on its draft 13th recommendation to include certain SVHC Candidate List substances in REACH Annex XIV (Authorisation List). This is an upstream step toward potential Annex XIV inclusion (which would later impose authorisation requirements and set latest application and sunset dates via subsequent Commission action). Compliance teams should review whether any recommended substances are used in products/processes and consider submitting comments and preparing for potential authorisation planning and supply-chain communication.
ECHA published the draft 13th recommendation for inclusion of Candidate List substances of very high concern (SVHCs) in REACH Annex XIV (Authorisation List) and opened a public consultation. This is a key downstream step in the SVHC pathway because Annex XIV listing can ultimately require companies to obtain authorisation for continued use/placing on the market of listed substances after specified sunset dates (once Annex XIV is formally amended via EU legislation). Compliance teams should review whether any substances relevant to their portfolios are covered and consider preparing comments and internal substitution/authorisation strategies.
ECHA opened a public consultation on its draft recommendation to the European Commission to include four SVHC Candidate List substances in REACH Annex XIV (Authorisation List). Stakeholders are invited to submit information (e.g., uses, volumes, potential exemptions, and supply chain impacts) to inform ECHA’s final recommendation. This is a proposed/pipeline step (not yet a legal Annex XIV amendment) but is highly relevant for companies using these substances, as Annex XIV listing can lead to authorisation obligations and potential phase-out/substitution planning.
ECHA opened a public consultation on its 13th draft recommendation for prioritising SVHCs for inclusion in REACH Annex XIV (Authorisation List). The recommendation status is shown as 'included in draft recommendation' with a consultation window from 02-Feb-2026 to 02-May-2026. While this is not yet a binding Annex XIV amendment, it is a key step toward future authorisation requirements (e.g., eventual latest application and sunset dates) for substances selected by the European Commission. Compliance teams should review whether any listed substances are used in their products/processes and consider submitting comments during the consultation period and preparing for potential downstream authorisation impacts if the Commission proceeds.
ECHA has opened a public consultation on its draft 13th recommendation of priority SVHCs from the Candidate List for possible inclusion in REACH Annex XIV (Authorisation List). The consultation window shown is 02 February 2026 through 02 May 2026. This is a key step in the SVHC-to-authorisation pipeline; if substances are later added to Annex XIV by the European Commission, authorisation requirements could apply for non-exempt uses after future latest application/sunset dates. Compliance teams should evaluate business impacts, substitution plans, and consider submitting comments/evidence during the consultation period.
ECHA opened a public consultation on its draft 13th recommendation for inclusion of certain Candidate List SVHCs in REACH Annex XIV (Authorisation List). This is a key SVHC-related downstream step: substances recommended for Annex XIV can later be added by the European Commission via amendment, triggering authorisation requirements (including latest application and sunset dates) for continued use. Consultation window shown is 02 Feb 2026 to 02 May 2026, with linked draft recommendation and supporting documents.
ECHA published its recommendation dated 18 November 2025 to the European Commission to include four SVHCs in REACH Annex XIV (Authorisation List): Melamine; S-(tricyclo[5.2.1.0²,⁶]deca-3-en-8(or 9)-yl) O-(isopropyl/isobutyl/2-ethylhexyl) O-(isopropyl/isobutyl/2-ethylhexyl) phosphorodithioate; Diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide; and Barium diboron tetraoxide. This is a pre-legislative step that can lead to future authorisation requirements (latest application/sunset dates) if adopted into Annex XIV by the European Commission. Compliance teams should track these substances and evaluate potential substitution/authorisation strategies.
ECHA has issued its 12th recommendation for priority substances to be included in REACH Annex XIV (Authorisation List). The recommendation, finalized on 18 November 2025, followed a public consultation from 7 February 2024 to 7 May 2024. Substances recommended include melamine (EC No. 203-615-4) and others from the Candidate List. The European Commission will now decide whether to add these substances to Annex XIV. If adopted, companies using these substances will need to apply for authorisation before the latest application date and cease use after the sunset date unless authorisation is granted.
ECHA issued its final (12th) recommendation to the European Commission to include four Candidate List SVHCs in REACH Annex XIV (Authorisation List). While this is not yet a binding Annex XIV amendment, it is a concrete step in the SVHC-to-authorisation pipeline and signals potential future authorisation obligations (i.e., continued use/placing on the market after any future sunset dates would require authorisation unless exemptions apply). Compliance teams should monitor the Commission’s subsequent Annex XIV amendment process and begin evaluating uses and substitution plans for the recommended substances.
ECHA published a final screening report (Final v1, dated 7 May 2025) assessing whether use of tetraethyllead (a substance subject to authorisation under REACH Annex XIV, Entry 55) in articles could trigger the need for an Annex XV restriction dossier under REACH Article 69(2). After screening available information sources (including registrations, authorisation applications, notifications of SVHCs in articles, SCIP, and other sources), ECHA reported it found no information indicating tetraethyllead is present in articles placed on the EU market, and therefore concluded there is currently no need to prepare an Annex XV restriction dossier. Compliance teams managing legacy Annex XIV substances should note ECHA’s documented conclusion and monitor for new evidence that could reopen Article 69(2) considerations.
Commission Regulation (EU) 2023/2482 amends REACH Annex XIV to align the latest application date and sunset date for DEHP (bis(2-ethylhexyl) phthalate, EC No. 204-211-0) when used in medical devices. This modification provides adjusted timing requirements for companies seeking authorisation for DEHP uses specifically in medical device applications, addressing the unique regulatory pathway for this sector.